This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Coronary heart disease (CHD); nephropathy	SNP rs560887; glucose-6-phosphatase catalytic subunit-related protein (IGRP; G6PC2)	A genome-wide association study suggests that a mutation in the *IGRP* gene could be a biomarker for susceptibility to CHD and nephropathy. Genetic analysis of three populations revealed that the rs560887 SNP in IGRP was significantly associated with reduced fasting plasma glucose levels ($p=3\times10^{-23}$), which has been implicated in cardiovascular disorders. Next steps include studying how IGRP variations control blood glucose and developing compounds that target IGRP.	Patent application filed for SNP rs560887 genetic testing; available for licensing through McGill University	Bouatia-Naji, N. *et al. Science*; published online May 1, 2008; doi:10.1126/science.1156849 **Contact:** Philippe Froguel, Imperial College London, London, U.K. e-mail: p.froguel@imperial.ac.uk